tbuckley/cabot-search huggingface dataset:
Gene expression profiling (GEP) to predict the primary site of metastatic neuroendocrine tumors (NETs) presenting with an unknown primary.
Authors: Eugene Woltering, Lowell Brian Anthony, Anne E. Diebold, J Philip Boudreaux, Yi-Zarn Wang
Journal: Journal of Clinical Oncology (2013)

4141 Background: NETs often present as liver metastasis with an unknown primary. Accurate subtyping of NETs has important clinical implications for staging and site-specific targeted therapy. Traditionally, the work-up to identify a primary NET as being lung, pancreatic or gut-based can be challenging and time-consuming. Methods: GEP was performed on formalin-fixed, paraffin-embedded tumor samples using a 92-gene RT-PCR assay (CancerTYPE ID, bioTheranostics Inc.) as part of the clinical work-up for patients diagnosed with NETs and unknown primaries. Results: Results were categorized by level of agreement (Table). Of the 39 patients tested with the assay, 82% presented with liver metastasis. Assay results from those patients with adequate work-up were concordant with clinical data in 77% (23/30) of cases. Surgery was performed in 12 of these cases and 100% accuracy of the molecular assay was confirmed, resulting in 75% of primary tumors being found in the gut and 25% in the pancreas or duodenum. Assay predictions were clinically plausible but inconsistent in 13% (4/30) of cases and were discordant with histology, IHC, imaging/radiological findings, and clinical impression in 10% of the cases. Conclusions: The 92-gene assay accurately predicted tumor subtype in patients presenting with NETs and an unknown primary. These findings have clinical utility for appropriate treatment selection, particularly where targeted therapies are available (everolimus, sunitinib). We believe the 92-gene assay can be useful in clinical management, and that our approach will lead to effective diagnosis and treatment algorithms to streamline extensive pre-operative work-up. [Table: see text]
Study of lapatinib (T) in combination with trastuzumab (T) in women heavily pretreated with HER2-positive metastatic breast cancer (MBC).
Authors: Javier Salvador, Manuel Ruiz Borrego, Maria Valero, Juan L. Bayo, Luis De La Cruz-Merino, FRancisco Carabantes, Maria Rodriguez de la Borbolla
Journal: Journal of Clinical Oncology (2013)

e11577 Background: The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and synergistic antitumour activity in models of HER2-overexpressing breast cancer.In heavily pre-treated pts, L+T is associated with improved outcomes compared to L alone and significantly improved progression-free survival (PFS), offering a chemotherapy-free option for patients with heavily pretreated human epidermal growth factor. (Kimberly L et al, 2012 JCO). Methods: We evaluated the safety and efficacy of L+T in patients with 1-4 prior (Median 3) lines of chemotherapy (CT) for HER2+ MBC.: 20 Pts with measurable, HER2+ MBC were eligible. Pts received every 3 weeks T (8 mg/kg loading then 6 mg/Kg) and daily L 1000 mg. Results: The characteristic of the all of pts included (20) are: median age 51.4 (32-68) Total number of cycles administered was 141. The median cycles administered per pts was 6 (range 1-18). Median follow-up was 6 months. Of the 18 pts with response assessment, the clinical benefit obtained was: 76,1% (5,9% PR + and 70,6% disease stabilization) with 95% CI 71.3%-80.9%. Disease progression was 17,6%. Of the 20 pts with a median follow up of 13,32 m (3-32), median PFS for these pts was 6 m. The one year OS % was 64,70% (56,7-72,7). All pts had received al least one line lapatinib prior (1-3). Toxicity was generally manageable. No major cardiac dysfunctions ocurred. Grade 3/4 treatment-related toxicities were uncommon (grade 3 diarrhea, 18%; grade 3 hepatic 7%. All others &lt; 3 %). Conclusions: L+T is an active regimen in HER2+ MBC. L+T showed high clinical benefit with manageable safety profile. Dual inhibition of HER2 might be a valid approach to treatment of Her-2 positive metastatic breast cancer.
ON THE DYNAMICS OF THE NEO-LVOT FOLLOWING TRANSCATHETER MITRAL VALVE REPLACEMENT WITH ANTERIOR LEAFLET LACERATION
Authors: Keshav Kohli, Zhenglun Alan Wei, Vahid Sadri, John Lisko, Jaffar Khan, Robert Lederman, Philipp Blanke, John Oshinski, Vasilis Babaliaros, Ajit Yoganathan
Journal: Journal of the American College of Cardiology (2020)
Effects of acute doxorubicin exposure on caspase-mediated apoptosis in cardiomyocytes.
Authors: Umut Demirci, Melek Yaman, Umit E. Bagriacik
Journal: Journal of Clinical Oncology (2013)

e12036 Background: Doxorubicin binds to DNA-associated enzymes, intercalates the base pairs of the DNA and induces apoptosis in cancerous and healthy tissues especially in cardiomyocytes. Caspase mediated apoptosis in cardiomyocytes remains largely unknown. We investigated the role of doxorubicin via caspase system on apoptosis of cardiomyocytes. Methods: H9C2ratcardiomyocytes were incubated with doxorubicin a concentration of 10 -6 Mfor 4 or 24 hours to perform gene expression and activity of caspases, respectively. Total RNA isolated and expression analysis were performed by real time PCR assay. Caspase activity was determined by colorimetric caspase assay kit. At least two fold increases in gene expression were accepted statistically significant. Results: In comparison to controls, bothof caspase expression and activity increased in doxorubicin-treated samples. Increase in expression of Caspase 9 and 2 as initiator caspases and caspases 7 and 3 as effector caspases were detected statistically higher than control values. In contrast, expression of caspase 1, 4, 6, 8 and 12 were detected lower than controls. Activity of both caspase 3 and 9 increased significantly. Conclusions: Acute doxorubicin administration caused a significant caspase activation on apoptosis of cardiomyocytes.
CATASTROPHIC THROMBOTIC STORM IN A YOUNG HISPANIC FEMALE DIAGNOSED WITH DEEP VEIN THROMBOSIS
Authors: Sharlene Medina Aviles, Dagmar Hernandez-Suarez, Jonathan Cordero-Jiménez, Jose G. Rodriguez Velez, Migdoel Cruz, Pedro Enrique Vargas Otero
Journal: Journal of the American College of Cardiology (2020)
ECHOCARDIOGRAPHIC VS. COMPUTED TOMOGRAPHIC-DERIVED ENERGY LOSS INDEX COMPARED TO INVASIVE AORTIC VALVE AREA IN AORTIC STENOSIS
Authors: Rick Gaines, Ramy Mando, Craig Tucker, Saba Assar, Aimee Hite, George S. Hanzel, Michael Gallagher, Francis Shannon, Amr E. Abbas
Journal: Journal of the American College of Cardiology (2020)
SAFETY AND EFFICACY OF A CONVERGENT HYBRID PROCEDURE USING CRYO AS ENDOCARDIAL ENERGY SOURCE FOR THE TREATMENT OF PERSISTENT AND LONGSTANDING PERSISTENT ATRIAL FIBRILLATION
Authors: Kevin Makati, Ramin Davoudi, Arnoldas Giedrimas, James M. Irwin, Andrew Sherman, Iraklis Gerogiannis, Nitesh Sood
Journal: Journal of the American College of Cardiology (2020)
BEMPEDOIC ACID EFFICACY AND SAFETY IN HIGH CVD RISK PATIENTS TREATED WITH OR WITHOUT EZETIMIBE: POOLED ANALYSIS OF 4 PHASE 3 CLINICAL TRIALS
Authors: Alberico L. Catapano, Harold Bays, Maciej Banach, P. Barton Duell, Ulrich Laufs, Lawrence A. Leiter, G.B. John Mancini, Kausik Kumar Ray, Diane MacDougall, Zhan Ye, Christie M. Ballantyne
Journal: Journal of the American College of Cardiology (2020)
INITIATION OF ANTI-HYPERTENSIVE DRUGS AND OUTCOMES IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF)
Authors: Shalini D. Allam, Poonam Bhyan, Phillip H. Lam, Cherinne Arundel, Charles Faselis, Prakash Deedwania, Richard M. Allman, Wilbert S. Aronow, Gregg C. Fonarow, Ali Ahmed
Journal: Journal of the American College of Cardiology (2020)
SEX DIFFERENCES IN STRESS TEST AND CCTA FINDINGS AND SYMPTOMS IN THE RANDOMIZED ISCHEMIA TRIAL
Authors: Harmony R. Reynolds, Leslee J. Shaw, Bernard Chaitman, Daniel S. Berman, Michael Picard, C. Noel Bairey Merz, Derek Cyr, Philippe Gabriel Steg, Renato Lopes, Jose Lopez-Sendon, Claes Held, Hanna Szwed, Roxy Senior, Gilbert Gosselin, Rajesh Nair, Ahmed Elghamaz, Olga Bockeria, Jiyan Chen, Alexander Chernyavskiy, Balram Bhargava, Jonathan D. Newman, Sasa Hinic, Krystyna Loboz-Grudzien, Angela Hoye, Judith S. Hochman
Journal: Journal of the American College of Cardiology (2020)
Safety and efficacy of pazopanib in heavily pretreated and treatment-naive patients with metastatic renal cell carcinoma (mRCC): A single center experience of the Medical University of Vienna, Austria.
Authors: Manuela Schmidinger, Marija Bojic, Ursula Maria Vogl, Christoph Klingler, Gero Kramer, Christoph Zielinski
Journal: Journal of Clinical Oncology (2012)

e15090 Background: Treatment with pazopanib was shown to improve objective response rates (ORR) and progression free survival (PFS) when compared to placebo in treatment-naïve or cytokine-pretreated patients with mRCC. We assessed the efficacy and safety of pazopanib in an unselected group of mRCC-patients at the Medical University of Vienna. Methods: Medical records of all patients who were treated with pazopanib between June 2010 and January 2012 were retrospectively reviewed. Pazopanib was prescribed at a dose of 800 mg daily. Treatment was given until disease progression or unacceptable toxicity. ORR was assessed by RECIST criteria. PFS and overall survival (OS) were calculated from the first day of pazopanib until progression and/or death, respectively. Results: Forty patients with a median age of 69 years (range 47-82) are currently evaluable for this analysis. The majority of patients (61%) presented with an ECOG Performance status of 0 and were classified as intermediate risk (55%) according to the MSKCC risk group classification. All patients had undergone nephrectomy and the majority (75%) had predominantly clear cell tumors. Most of the patients (66%) were diagnosed with three or more metastatic sites. Eighty percent of the patients were heavily pretreated, most commonly with three or more different types of targeted agents. Eight patients (20%) received pazopanib in first-line. Objective remission and disease stabilization were observed in 27% and 30% of the entire population. PFS and OS were 5 months (95%CI 3.07-6.86) and not reached, respectively. The most commonly observed all grade toxicities included fatigue (97%), anorexia (78%), hypertension (82%), diarrhoea (73%), nausea (62%) and vomiting (54%). The most common grade 3 or 4 toxicities were fatigue (68%), hypertension (47%) and diarrhoea (29%). Conclusions: Pazopanib appears effective in the setting of extensively pretreated patients. A later stage of the disease might have led to the unexpected higher incidence of off-target side effects such as fatigue and gastro-intestinal symptoms.
Abstract 141: Resuscitation Time Bias in an Observational Study of Mechanical Chest Compression CPR
Authors: Michael K Levy, Karl B Kern, Dana Yost, Bjarne Madsen Hardig, Fred W Chapman
Journal: Circulation (2018)

Recent observational studies have found associations between poorer outcomes and treatment that included mechanical CPR devices, contradicting findings from randomized trials. Resuscitation time bias is a systematic error occurring in observational studies of interventions applied to pulseless patients later in resuscitation attempts. Previous observational studies lack data on duration of resuscitation, a factor strongly related to outcome. We retrospectively analyzed cardiac arrest data to learn how resuscitation time and device use relate to clinical outcomes, and determine whether resuscitation time bias was present. Methods and Results: We analyzed data from all 49 patients with ventricular fibrillation, out-of-hospital cardiac arrest treated by our emergency medical service in one year. We compared 19 patients who received only standard manual CPR (the sCPR group) to 30 patients who received manual followed by mechanical CPR (the mCPR group). Response to CPR differed between groups even before device application. All sCPR patients achieved return of spontaneous circulation (ROSC), and did so after a median (IQR) of 3.3 (2.2-5.1) minutes of manual CPR. Patients in the mCPR group failed to get ROSC through 6.9 (5.3-11.0) min of manual CPR; mCPR patients that did get ROSC did so after 11.2 (5.7-23.8) additional minutes of CPR, delivered by a mechanical device. mCPR patients also received significantly more defibrillations and ALS drugs. ROSC and survival to hospital discharge were higher in the sCPR than the mCPR group (100% vs. 70%, P = 0.008; 74% vs. 43%, P = 0.045). Conclusion: Only patients remaining pulseless after early resuscitation efforts received mechanical CPR. Consequently, mechanical CPR devices assisted by facilitating prolonged treatment of patients who already had lower chances of survival before device application. Resuscitation time bias was present, and must be considered when interpreting registry reports comparing sCPR and mCPR.
PREVALENCE, CHARACTERISTICS AND OUTCOMES OF COCAINE-INDUCED MYOCARDIAL INFARCTION
Authors: Bertrand F. Ebner, Igor Vaz, Camilo Gomez, Andrew Scheinberg, Jonatan Nunez Breton, Cesar Mendoza-Trauco, Eduardo De Marchena, Carlos Enrique Alfonso, Alexandre Ferreira
Journal: Journal of the American College of Cardiology (2020)
BLOOD FLOW RESTRICTED TRAINING STIMULATES ANGIOGENESIS: NEW APPROACH TO POST-INTERVENTIONAL REHABILITATION OF PATIENTS WITH LOWER LIMBS ISCHEMIA
Authors: Jakub Krezel, Paulina Klapacz, Aleksandra Wlodarczyk, Mikolaj Maga, Agnieszka Trynkiewicz, Martyna Schönborn, Agnieszka Wachsmann-Maga, Pawel Maga
Journal: Journal of the American College of Cardiology (2020)
Radiation-induced damage of the rat intestine after external beam irradiation of the liver.
Authors: Silke Cameron, Antonia Schwartz, Sadaf Sultan, Inga-Marie Schaefer, Margret Rave-Fraenk, Hans Christiansen, Giuliano Ramadori
Journal: Journal of Clinical Oncology (2012)

e21128 Background: Radiotherapy alone or in combination with systemic therapies, is a major tool for local tumor control. Although organ-targeting techniques have greatly been improved over the past years, radiation enteropathy is a dose-limiting factor for effective radiotherapy. The out-of-field effects on the intestine, caused by radiation treatment of a parenchymatous organ, have not previously been studied. Methods: A single dose of 25 Gray was administered percutaneously to the liver of male Wistar rats after a planning CT-scan. Sham-irradiated animals served as controls. At 1, 6, 24, 96 hours, 1.5 and 3 months the duodenum, jejunum, ileum and distal colon were removed, washed and deep-frozen or prepared for paraffin staining. Results: All animals survived the treatment. Epithelial cell damage occurred in all small-intestinal segments. However, prolonged denudation of the villi together with destruction of the crypt lining was only observed in the ileum, which only received scattered radiation. Whilst the intestinal lining in the duodenum and jejunum was restored at the end of the study, in the ileum, tissue regeneration was deficient. In the colon, changes were minor. Immunhistochemical staining showed radiation mucositis with granulocyte (MP0+) infiltration from 1 to 24 hours in the duodenum and jejunum, when ED1+ macrophages, CD3+ T-lymphocytes, and CD34+ hematopoietic precursor cells were recruited, accompanied by an increase in the chemokines MCP-1, MIP-1α, MIP3α and Il-8. In the ileum, early granulocyte infiltration was delayed but continuous. Recruitment of macrophages and lymphocytes was deficient and induction of chemokines as of the adhesion molecules PECAM-1, ICAM-1 was lacking. Conclusions: Post-irradiation damage to the ileum was delayed and followed by an altered repair process with structural changes of the villi. The observed changes might result from a higher sensitivity to oxidative stress mechanisms with subsequent damage of the regenerative capacity of the crypt-villus axis, accompanied by a sustained “inflammatory response” and vascular damage with a lack of regeneratory cell recruitment.
AORTO-RIGHT ATRIAL FISTULA FOLLOWING PERCUTANEOUS TRANSCATHETER AORTIC VALVE REPLACMENT
Authors: Ameer Musa, Tisha Marie Suboc, Karolina Marinescu, Anupama Rao, Neeraj Jolly, Deborah Tabachnick, Chadrick Cross, Antone Tatooles
Journal: Journal of the American College of Cardiology (2020)
Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.
Authors: Rebecca Suk Heist, Leena Gandhi, Geoffrey Shapiro, Naiyer A. Rizvi, Howard A. Burris, Johanna C. Bendell, Jose Baselga, Scott B Yerganian, Karl Hsu, Janet Ogden, Loïc Vincent, Oliver von Richter, Giuseppe Locatelli, Ekatherine Asatiani, Jeffrey R. Infante
Journal: Journal of Clinical Oncology (2013)

2530 Background: PI3K/mTOR and MAPK signaling pathways are often deregulated in tumors. Simultaneous inhibition of these pathways with the MEK1/2 inhibitor, pimasertib, plus the dual PI3K/mTOR inhibitor, SAR245409, (ClinicalTrials.gov NCT01390818) was investigated. Methods: This was a phase Ib, modified 3+3, dose-escalation trial in patients (pts) with advanced solid tumors. Pts received pimasertib and SAR245409 at the following dose levels (DLs): DL1, 15/30; DL2a, 30/30; DL2b, 15/50; DL3, 30/50; DL4a, 60/50; DL4b, 30/70; DL5, 60/70; DL6a, 90/70; DL6b 60/90 and DL7, 90/90 mg (once-daily, qd). After the qd maximum tolerated dose (MTD) was established, twice-daily (bid) dosing was tested: DL1a, 60/30; DL1b, 45/50 and DL2 60/50 mg bid. A recommended phase II dose (RP2D) was determined. Enrollment continued at the RP2D in four expansion cohorts (18 pts each): dual KRAS/PIK3CA mutated (mt) colorectal cancer (CRC), triple-negative breast cancer, KRAS mt non-small cell lung cancer (NSCLC) and BRAFmt melanoma. Results: 53 pts were treated qd and 7 pts bid. The most common tumors were CRC (n=16), NSCLC (n=8), ovarian and pancreatic (n=7, each). At DL6b 2/3 pts had dose-limiting toxicities (DLTs; both grade [Gr] 3 nausea/vomiting). DL6a was confirmed as the MTD for the qd schedule. At bid DL1a 2/4 pts (both Gr 3 skin rash) and at DL1b 2/3 pts (Gr 3 skin rash and Gr 3 asthenia) had DLTs. DL5 was the RP2D based on tolerability after prolonged exposure. The most common adverse events in qd schedule were: rash (62%, 13% Gr 3), diarrhea (56%, 4% Gr 3), fatigue (51%, 2% Gr 3), nausea (49%, 2% Gr 3), vomiting (45%, 2% Gr 3), peripheral edema and pyrexia (34%, each) and visual impairment with underlying serous retinal detachment (21%). Preliminary pharmacokinetic results suggest no drug-drug interaction. There were 4 partial responses: KRAS mt CRC (n=1) and low-grade ovarian cancer (n=3, 1 KRAS mt/PIK3CA mt and 2 wild-type). Enrollment in expansion cohorts at DL5 is ongoing. Conclusions: Continuousqd dosing of pimasertib and SAR245409 is tolerated and has shown signs of activity. Phase II trials are being planned. Clinical trial information: NCT01390818.
LONG-TERM PREDICTION OF CARDIAC EVENTS IN ASYMPTOMATIC SUBJECTS BY INTEGRATING NOVEL CIRCULATING AND IMAGING BIOMARKERS USING MACHINE LEARNING
Authors: Andrew Lin, Balaji Tamarappoo, Frederic Commandeur, Priscilla McElhinney, Sebastien Cadet, Markus Goeller, Xi Chen, Aryabod Razipour, Heidi Gransar, Stephanie Cantu, Robert Miller, Nathan D. Wong, Stephan Achenbach, Alan Rozanski, Daniel S. Berman, Piotr Slomka, Damini Dey
Journal: Journal of the American College of Cardiology (2020)
IMMUNE CHECKPOINT INHIBITOR INDUCED MYOCARDITIS MIMICKING MYOCARDIAL INFARCTION
Authors: Jinglin Gu, Yuxi Li, Lan Gao, Pengkang He, Dan Liu, Changsong Qi, Jifang Gong, Xi Cao, Wei Ma, He Wang, Songyun Chu, Yueyuan Li, Wenhui Ding, Lin Shen, Jianping Li
Journal: Journal of the American College of Cardiology (2020)
Interleukin-21 (IL-21): Tolerability and anti-tumor activity following two 5-day cycles in patients with stage IV melanoma (MM) or renal cell carcinoma (RCC)
Authors: J. A. Thompson, B. D. Curti, B. G. Redman, J. S. Weber, S. S. Agarwala, E. L. Sievers
Journal: Journal of Clinical Oncology (2006)

2505 Background: IL-21 enhances NK cell activity and the proliferation and activation of CD8+ T cells. A Phase 1 outpatient dose-escalation trial of IL-21 in patients with MM or RCC established a maximum tolerated dose and demonstrated biologic effects as measured by increased soluble CD25 levels and decreased lymphocyte counts. Partial responses (PR) were observed in 2 patients with RCC (J Immunother. 2005; 28:641–642). Methods: IL-21 was administered by intravenous push at 30 μg/kg/day for two 5-day cycles separated by a 9- or 16-day rest to a total of 34 patients (18 MM and 16 RCC) to further characterize safety and evaluate preliminary signs of anti-tumor activity. Results: All patients received 2 cycles of treatment with the exception of one patient who discontinued secondary to pleural effusion. Common drug-related Grade 1–2 adverse events (AEs) included pyrexia (n=27), fatigue (n=25), chills (n=18), headache (n=18), and rash (n=16). Related Grade 3 AEs included pleural effusion, abdominal pain, hypophosphatemia, and thrombocytopenia (n=1 each). Laboratory abnormalities commonly observed were decreased lymphocytes (n=31), platelets (n=31), albumin (n=29), and hemoglobin (n=27); increased triglycerides (n=27) and ALT (n=26). Except for lymphopenia (an expected pharmacodynamic response), most toxicities were Grade 1–2. AEs and laboratory abnormalities were generally transient. Final study results, including response data, will be presented. To date, of 28 patients evaluable for response (i.e., those who received at least 8 of 10 doses and have had a final evaluation), one PR has been confirmed in a patient with MM and 18 patients have stable disease two months following initiation of therapy. Conclusions: Two 5-day outpatient cycles of IL-21 at 30 μg/kg/day have been reasonably well tolerated and have demonstrated preliminary evidence of anti-tumor activity in patients with advanced MM or RCC. [Table: see text]
3D ECHOCARDIOGRAPHIC ASSESSMENT OF MITRAL ANNULAR DIMENSIONS AND RISK OF MITRAL STENOSIS AFTER TRANSCATHETER MITRAL VALVE REPAIR
Authors: Mohammed Hasan Khan, Syed Zaid, Joshua Goldberg, Tanya Dutta, Cenap Undemir, Joanne Bennett, Martin Cohen, Steven Lansman, Gilbert Tang, Hasan Ahmad, Daniel Spevack
Journal: Journal of the American College of Cardiology (2020)
Resource-rationality and dynamic coupling of brains and social environments
Authors: Don Ross
Journal: Behavioral and Brain Sciences (2020)

Leider and Griffiths clarify the basis for unification between mechanism-driven and solution-driven disciplines and methodologies in cognitive science. But, two outstanding issues arise for their model of resource-rationality: human brains co-process information with their environments, rather than merely adapt to them; and this is expressed in methodological differences between disciplines that complicate Leider and Griffiths' proposed structural unification.
Covid-19: Trump sought to buy vaccine developer exclusively for US, say German officials
Authors: Owen Dyer
Journal: BMJ (2020)

The US president, Donald Trump, made secret overtures to the German company CureVac—one of the leading contenders to create a covid-19 vaccine—in the hope of luring it to the United States, say senior officials in the German government.

Germany’s Welt am Sonntag newspaper reported that the offer, valued at about $1bn (£829m; €912m), stipulated that any vaccine the company developed would be “only for the USA.”1 The company has often said that its products would be offered to all countries.

Senior German officials confirmed the reports and criticised the US government’s actions. Horst Seehofer, interior minister, when asked to confirm the newspaper’s report, said that he had “heard from several other …